{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:32:44Z","timestamp":1793503964776,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virologica Sinica"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.virs.2022.06.006","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T19:24:24Z","timestamp":1656185064000},"page":"716-723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China"],"prefix":"10.1016","volume":"37","author":[{"given":"Haisu","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankai","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengchun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingkun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuegao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1485-1626","authenticated-orcid":false,"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7511-3091","authenticated-orcid":false,"given":"Ying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virs.2022.06.006_bib1","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups b and d","volume":"81","author":"Abbink","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2022.06.006_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqab010","article-title":"Overview of approved and upcoming vaccines for sars-cov-2: a living review","volume":"2","author":"Alderson","year":"2021","journal-title":"Oxf Open Immunol"},{"key":"10.1016\/j.virs.2022.06.006_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/104303404322886147","article-title":"Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines","volume":"15","author":"Aste-Amezaga","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.virs.2022.06.006_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 hiv-1 env vaccine (ipcavd 001)","volume":"207","author":"Baden","year":"2013","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.virs.2022.06.006_bib5","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/infdis\/jiu485","article-title":"Induction of hiv-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 hiv-1 vaccination of humans","volume":"211","author":"Baden","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.virs.2022.06.006_bib6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/infdis\/jis671","article-title":"Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 hiv-1 env vaccine in healthy adults (ipcavd 001)","volume":"207","author":"Barouch","year":"2013","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.virs.2022.06.006_bib7","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.virs.2022.06.006_bib8","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jcv.2012.04.009","article-title":"Adenovirus infections in bordeaux university hospital 2008-2010: clinical and virological features","volume":"54","author":"Berciaud","year":"2012","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.virs.2022.06.006_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/JVI.06254-11","article-title":"Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection","volume":"86","author":"Bradley","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2022.06.006_bib10","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.4161\/hv.26038","article-title":"Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults","volume":"9","author":"Creech","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virs.2022.06.006_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/biomedicines7030061","article-title":"Perspective on adenoviruses: epidemiology, pathogenicity, and gene therapy","volume":"7","author":"Crenshaw","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.virs.2022.06.006_bib12","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (ad26) and ad35 vaccine vectors bypass immunity to ad5 and protect nonhuman primates against ebolavirus challenge","volume":"85","author":"Geisbert","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2022.06.006_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1556\/EuJMI.4.2014.1.2","article-title":"Human adenovirus: viral pathogen with increasing importance","volume":"4","author":"Ghebremedhin","year":"2014","journal-title":"Eur J Microbiol Immunol (Bp)"},{"key":"10.1016\/j.virs.2022.06.006_bib14","first-page":"586","article-title":"Safety and immunogenicity of heterologous and homologous two dose regimens of ad26- and mva-vectored ebola vaccines: a randomized, controlled phase 1 study","author":"Goldstein","year":"2020","journal-title":"J\u00a0Infect Dis. Jiaa"},{"key":"10.1016\/j.virs.2022.06.006_bib15","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/1873-3468.13849","article-title":"Adenoviruses - infection, pathogenesis and therapy","volume":"594","author":"Greber","year":"2020","journal-title":"FEBS Lett."},{"key":"10.1016\/j.virs.2022.06.006_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12985-021-01661-6","article-title":"Human adenoviruses in paediatric patients with respiratory tract infections in beijing, China","volume":"18","author":"Huang","year":"2021","journal-title":"Virol. J."},{"key":"10.1016\/j.virs.2022.06.006_bib17","first-page":"10","article-title":"Genomic analysis of a large set of currently-and historically-important human adenovirus pathogens","volume":"7","author":"Ismail","year":"2018","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.virs.2022.06.006_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3201\/eid2402.171407","article-title":"Adenovirus type 4 respiratory infections among civilian adults, northeastern United States, 2011-2015(1)","volume":"24","author":"Kajon","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.virs.2022.06.006_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041936","article-title":"A\u00a0phase i double blind, placebo-controlled, randomized study of a multigenic hiv-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults","volume":"7","author":"Keefer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.virs.2022.06.006_bib20","first-page":"2345","article-title":"Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver","volume":"18","author":"Kuriyama","year":"1998","journal-title":"Anticancer Res."},{"key":"10.1016\/j.virs.2022.06.006_bib21","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rad26 and rad5 vector-based heterologous prime-boost covid-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.virs.2022.06.006_bib22","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rad26 and rad5 vector-based heterologous prime-boost covid-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.virs.2022.06.006_bib23","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-0036-1584923","article-title":"Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention","volume":"37","author":"Lynch","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.virs.2022.06.006_bib24","doi-asserted-by":"crossref","first-page":"15265","DOI":"10.1128\/JVI.79.24.15265-15276.2005","article-title":"Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy","volume":"79","author":"Madisch","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2022.06.006_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the sars-cov-2 pandemic","volume":"6","author":"Mendonca","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.virs.2022.06.006_bib26","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2019.1588113","article-title":"A\u00a0review of 65 years of human adenovirus seroprevalence","volume":"18","author":"Mennechet","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.virs.2022.06.006_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125954","article-title":"A\u00a0phase i double blind, placebo-controlled, randomized study of the safety and immunogenicity of an adjuvanted hiv-1 gag-pol-nef fusion protein and adenovirus 35 gag-rt-int-nef vaccine in healthy hiv-uninfected african adults","volume":"10","author":"Omosa-Manyonyi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.virs.2022.06.006_bib28","doi-asserted-by":"crossref","first-page":"e1532","DOI":"10.1093\/cid\/ciaa1277","article-title":"Human adenovirus 7-associated hemophagocytic lymphohistiocytosis-like illness: clinical and virological characteristics in a cluster of five pediatric cases","volume":"73","author":"Otto","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virs.2022.06.006_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078679","article-title":"A\u00a0phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in burkinabe healthy adults 18 to 45 years of age","volume":"8","author":"Ou\u00e9draogo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.virs.2022.06.006_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2189","article-title":"Epidemiology of human adenovirus associated with respiratory infection in southern Brazil","volume":"31","author":"Pscheidt","year":"2021","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.virs.2022.06.006_bib31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.virs.2022.06.006_bib32","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/srep01812","article-title":"Molecular evolution of human adenoviruses","volume":"3","author":"Robinson","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virs.2022.06.006_bib33","article-title":"Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of ad26.Rsv.Pref in a human challenge study","author":"Sadoff","year":"2021","journal-title":"J\u00a0Infect Dis. Jiab: 003"},{"key":"10.1016\/j.virs.2022.06.006_bib34","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose ad26.Cov2.S vaccine against covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.virs.2022.06.006_bib35","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M20-5306","article-title":"A\u00a0double-blind, randomized, placebo-controlled phase 1 study of ad26.Zikv.001, an ad26-vectored anti-zika virus vaccine","volume":"174","author":"Salisch","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.virs.2022.06.006_bib36","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/oxfordjournals.aje.a113563","article-title":"Worldwide epidemiology of human adenovirus infections","volume":"117","author":"Schmitz","year":"1983","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.virs.2022.06.006_bib37","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMc2036242","article-title":"Safety and efficacy of the bnt162b2 mrna covid-19 vaccine","volume":"384","author":"Skowronski","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.virs.2022.06.006_bib38","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1016\/j.vaccine.2011.03.042","article-title":"Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and aids patients in guangzhou, southern China","volume":"29","author":"Sun","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.virs.2022.06.006_bib39","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virs.2022.06.006_bib40","doi-asserted-by":"crossref","first-page":"803","DOI":"10.21037\/jtd.2016.03.29","article-title":"Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China","volume":"8","author":"Tian","year":"2016","journal-title":"J.\u00a0Thorac. Dis."},{"key":"10.1016\/j.virs.2022.06.006_bib41","first-page":"1577","article-title":"Safety and efficacy of the bnt162b2 mrna covid-19 vaccine","volume":"384","author":"Vergnes","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.virs.2022.06.006_bib42","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1128\/jcm.21.3.403-408.1985","article-title":"Molecular epidemiology of adenoviruses: global distribution of adenovirus 7 genome types","volume":"21","author":"Wadell","year":"1985","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.virs.2022.06.006_bib43","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1038\/emi.2014.30","article-title":"Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China","volume":"3","author":"Wang","year":"2014","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.virs.2022.06.006_bib44","doi-asserted-by":"crossref","first-page":"e00026","DOI":"10.1128\/JVI.00026-18","article-title":"Interaction of human enterochromaffin cells with human enteric adenovirus 41 leads to serotonin release and subsequent activation of enteric glia cells","volume":"92","author":"Westerberg","year":"2018","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2022.06.006_bib45","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1016\/j.vaccine.2015.08.056","article-title":"Recombinant low-seroprevalent adenoviral vectors ad26 and ad35 expressing the respiratory syncytial virus (rsv) fusion protein induce protective immunity against rsv infection in cotton rats","volume":"33","author":"Widjojoatmodjo","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.virs.2022.06.006_bib46","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3201\/eid1210.060078","article-title":"Chimpanzee adenovirus antibodies in humans, sub-saharan africa","volume":"12","author":"Xiang","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.virs.2022.06.006_bib47","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/sj.gt.3302590","article-title":"Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against hiv","volume":"12","author":"Xin","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.virs.2022.06.006_bib48","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.3389\/fmicb.2018.03040","article-title":"Seroprevalence of neutralizing antibodies to human adenovirus type 4 and 7 in healthy populations from southern China","volume":"9","author":"Ye","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.virs.2022.06.006_bib49","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/jmv.23325","article-title":"Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China","volume":"84","author":"Yu","year":"2012","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.virs.2022.06.006_bib50","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/21645515.2016.1165908","article-title":"Adenoviral vector-based strategies against infectious disease and cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virs.2022.06.006_bib51","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/jmv.23546","article-title":"Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults","volume":"85","author":"Zhang","year":"2013","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.virs.2022.06.006_bib52","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1038\/emi.2017.29","article-title":"Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in southern China","volume":"6","author":"Zheng","year":"2017","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.virs.2022.06.006_bib53","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored covid-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"}],"container-title":["Virologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X22001122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X22001122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:18:56Z","timestamp":1761851936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1995820X22001122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1995820X22001122"],"URL":"https:\/\/doi.org\/10.1016\/j.virs.2022.06.006","relation":{},"ISSN":["1995-820X"],"issn-type":[{"value":"1995-820X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China","name":"articletitle","label":"Article Title"},{"value":"Virologica Sinica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virs.2022.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}